Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Critical Therapeutics
Officials from Critical Therapeutics report on recent developments
April 11th, 2007
Officials from Critical Therapeutics report on recent developments. This trend article is an immediate alert from NewsRx to identify the most recent news developments at Critical Therapeutics. Report 1: Critical Therapeutics, Inc. (Nasdaq: CRTX) announced that Beckman Coulter, Inc. has exercised its option to continue to license patent rights relating to the use of High Mobility Group Box 1 (HMGB1) technology to develop an immunoassay for detection and diagnosis of inflammatory diseases. Beckman Coulter has paid Critical Therapeutics a product development fee as a result of exercising its option and has agreed to begin formal product development of...
Source: Medical Patent Law Weekly (2007-04-11)
|
